Velsovir 400 mg+100 mg (Tablet)
Unit Price: ৳ 1,000.00 (1 x 7: ৳ 7,000.00)
Strip Price: ৳ 7,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sofosbuvir velpatasvir |
| Company | Unimed unihealth pharmaceuticals ltd |
Indications
- indicated for the treatment of chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection
- for use in combination with ribavirin in patients with decompensated cirrhosis
- for use in adult and pediatric patients 3 years of age and older
Pharmacology
- Sofosbuvir is an inhibitor of HCV NS5B RNA-dependent RNA polymerase
- Velpatasvir is an inhibitor of the HCV NS5A protein
- GS-461203 is the pharmacologically active uridine analog triphosphate
- GS-461203 inhibits the polymerase activity of HCV genotypes 1b, 2a, 3a, and 4a
Dosage & Administration
- recommended dosage of Sofosbuvir & Velpatasvir in adults is one tablet taken orally once daily
- for pediatric patients 3 years and older, dosage is based on weight
- dosage of ribavirin is based on weight and can be adjusted based on hemoglobin and creatinine clearance
Interaction
- Sofosbuvir and Velpatasvir are substrates of drug transporters P-gp and BCRP
- Velpatasvir is an inhibitor of drug transporters P-gp, BCRP, OATP1B1, OATP1B3 and OATP2B1
Contraindications
- contraindicated in patients for whom Ribavirin is contraindicated
Side Effects
- common side effects include fatigue, nausea, headache, anemia, diarrhea, insomnia, pruritus, muscle spasm, dyspnea, and cough
- rare adverse events include reduced hemoglobin level, lymphocyte count, neutrophil count, and platelet count
Pregnancy & Lactation
- contraindicated in pregnant women and in men whose female partners are pregnant when administered with Ribavirin
Precautions & Warnings
- risk of Hepatitis B Virus Reactivation in Patients Coinfected with HCV and HBV
- serious symptomatic bradycardia when coadministered with Amiodarone
- risk of bradycardia increased in patients taking beta blockers or with underlying cardiac comorbidities
Use in Special Populations
- age does not have a clinically relevant effect on exposure to Sofosbuvir, GS-331007 or Velpatasvir
- pharmacokinetics of Sofosbuvir and GS-331007 are affected in patients with renal impairment
- pharmacokinetics of Velpatasvir are not affected in patients with severe renal impairment
- pharmacokinetics of Sofosbuvir and GS-331007 are affected in patients with hepatic impairment
- pharmacokinetics of Velpatasvir are not affected in patients with moderate or severe hepatic impairment
Overdose Effects
- no specific antidote available
- monitor for evidence of toxicity and provide general supportive measures
- hemodialysis can efficiently remove the predominant circulating metabolite of Sofosbuvir
Therapeutic Class
- Hepatic viral infections (Hepatitis C)
Storage Conditions
- store in a cool and dry place (preferably below 30°C)
- keep out of reach of children